Alvin T George1, Betty H Li2, Robert E Carroll3. 1. Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, 840 S Wood St (M/C 716), Chicago, IL, 60612, USA. 2. Department of Internal Medicine, University of Chicago Medicine, Chicago, IL, USA. 3. Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, 840 S Wood St (M/C 716), Chicago, IL, 60612, USA. rcarroll@uic.edu.
Abstract
BACKGROUND: Teduglutide, a glucagon-like peptide 2 analog, has demonstrated efficacy in treating adult patients with short bowel syndrome (SBS) and dependence on parenteral nutrition (PN), but its role in chronic malabsorptive states that do not necessitate PN remains uncertain. AIMS: To evaluate teduglutide use beyond its approved indications and to discuss the results of this adjunctive treatment in patients resistant to established therapy. RESULTS: This series reports four patients treated with teduglutide off-label. The first case had Crohn's disease (CD) with persistent colocutaneous fistulae that demonstrated complete closure after 8 months of teduglutide therapy. The second case involved a PN-dependent CD patient with persistent fistulae and intra-abdominal abscesses who weaned off PN and had a significant improvement in her nutritional status after 3 months of teduglutide therapy. The third case had CD complicated by severe malnutrition and previous PN-associated line infections, but by 9 months of teduglutide therapy, she gained 5 kg and no longer required re-initiation of PN. The fourth case had a high-output diverting ileostomy with resultant impaired healing of a stage IV decubitus ulcer, and after 2 months of therapy, the patient's pre-albumin increased by 250% and the ulcer had decreased by 40% in size. CONCLUSION: The use of teduglutide might be broadened to include patients with functional SBS not meeting strict criteria for intestinal failure. Further studies should evaluate the efficacy of teduglutide in patients who may require short-term small intestine rehabilitation or who have chronically impaired absorptive capacity not yet requiring PN.
BACKGROUND:Teduglutide, a glucagon-like peptide 2 analog, has demonstrated efficacy in treating adult patients with short bowel syndrome (SBS) and dependence on parenteral nutrition (PN), but its role in chronic malabsorptive states that do not necessitate PN remains uncertain. AIMS: To evaluate teduglutide use beyond its approved indications and to discuss the results of this adjunctive treatment in patients resistant to established therapy. RESULTS: This series reports four patients treated with teduglutide off-label. The first case had Crohn's disease (CD) with persistent colocutaneous fistulae that demonstrated complete closure after 8 months of teduglutide therapy. The second case involved a PN-dependent CDpatient with persistent fistulae and intra-abdominal abscesses who weaned off PN and had a significant improvement in her nutritional status after 3 months of teduglutide therapy. The third case had CD complicated by severe malnutrition and previous PN-associated line infections, but by 9 months of teduglutide therapy, she gained 5 kg and no longer required re-initiation of PN. The fourth case had a high-output diverting ileostomy with resultant impaired healing of a stage IV decubitus ulcer, and after 2 months of therapy, the patient's pre-albumin increased by 250% and the ulcer had decreased by 40% in size. CONCLUSION: The use of teduglutide might be broadened to include patients with functional SBS not meeting strict criteria for intestinal failure. Further studies should evaluate the efficacy of teduglutide in patients who may require short-term small intestine rehabilitation or who have chronically impaired absorptive capacity not yet requiring PN.
Authors: P B Jeppesen; B Hartmann; J Thulesen; J Graff; J Lohmann; B S Hansen; F Tofteng; S S Poulsen; J L Madsen; J J Holst; P B Mortensen Journal: Gastroenterology Date: 2001-03 Impact factor: 22.682
Authors: Alexander Perez; Mark Duxbury; Flavio G Rocha; Anthony P Ramsanahie; Robert S Farivar; Heike Varnholt; Hiromichi Ito; Helen Wong; Jan Rounds; Michael J Zinner; Edward E Whang; Stanley W Ashley Journal: JPEN J Parenter Enteral Nutr Date: 2005 Mar-Apr Impact factor: 4.016
Authors: Stephen J D O'Keefe; Palle B Jeppesen; Richard Gilroy; Marek Pertkiewicz; Johane P Allard; Bernard Messing Journal: Clin Gastroenterol Hepatol Date: 2013-01-17 Impact factor: 11.382
Authors: Douglas L Seidner; Ken Fujioka; Joseph I Boullata; Kishore Iyer; Hak-Myung Lee; Thomas R Ziegler Journal: Nutr Clin Pract Date: 2018-05-15 Impact factor: 3.080
Authors: David L Sigalet; Laurie E Wallace; Jens J Holst; Gary R Martin; Tatsuru Kaji; Hiroaki Tanaka; Keith A Sharkey Journal: Am J Physiol Gastrointest Liver Physiol Date: 2007-03-29 Impact factor: 4.052
Authors: Palle B Jeppesen; Marek Pertkiewicz; Bernard Messing; Kishore Iyer; Douglas L Seidner; Stephen J D O'keefe; Alastair Forbes; Hartmut Heinze; Bo Joelsson Journal: Gastroenterology Date: 2012-09-11 Impact factor: 22.682
Authors: Lauren K Schwartz; Stephen J D O'Keefe; Ken Fujioka; Simon M Gabe; Georg Lamprecht; Ulrich-Frank Pape; Benjamin Li; Nader N Youssef; Palle B Jeppesen Journal: Clin Transl Gastroenterol Date: 2016-02-04 Impact factor: 4.488